In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Esperion, with a price target of $16.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Joseph Pantginis has given his Buy rating due to a combination of factors including Esperion’s strong 2025 execution and positioning for further growth. He highlights that U.S. sales of NEXLETOL/NEXLIZET rose sharply year over year, supported by robust prescription trends and broadening market access, while real-world data confirm durable LDL-C reductions that should underpin wider clinical adoption.
Pantginis also points to the company’s expanding cardiometabolic platform and long-term “Vision 2040” strategy, which aim to build a multiproduct, blockbuster-scale franchise. The Corstasis acquisition, advancement of triple-combination BDA programs, and progress on the next-generation ACLY inhibitor ESP-2001 together reinforce his view that Esperion has meaningful strategic momentum and a pipeline capable of sustaining value creation beyond the near term.
In another report released on March 3, Needham also maintained a Buy rating on the stock with a $5.00 price target.
Based on the recent corporate insider activity of 28 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ESPR in relation to earlier this year.